Wells Fargo initiated coverage of Medline (MDLN) with an Equal Weight rating and $42 price target The firm sees Medline as a structural winner with clear line of sight to share gains. Strong prime vendor signings provide high visibility to near-term growth, Wells adds. However, the firm says valuation leaves it on the sidelines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Medline initiated with a Buy at TD Cowen
- Medline initiated with a Buy at BTIG
- Medline initiated with an Outperform at Mizuho
- Medline: Durable Moat, Secular Tailwinds, and Attractive Valuation Support Buy Rating
- Medline: Durable Growth, Expanding Market Share, and Margin Upside Support Buy Rating and $46 Target